Pirbuterol

Summary

Pirbuterol (CHEMBL1094966) is an approved small molecule (ATC R03CC07); indicated across 1 condition including obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03CC07 (+1 more)
• Indications: 1 condition
• Chemistry: 240.3 Da · C12H20N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1094966
Name	Pirbuterol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4845
ATC	R03CC07, R03AC08
Molecular formula	C12H20N2O3
Molecular weight	240.3
InChIKey	VQDBNKDJNJQRDG-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(C1=NC(=C(C=C1)O)CO)O

IUPAC name: 6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol

Also known as: ARA-211, Pirbuterol, Pyrbuterol, pirbuterol, PIRBUTEROL

Parent form; salt/anhydrous children: CHEMBL1200444, CHEMBL1997417, CHEMBL3989646

Patent coverage: 4,247 distinct patent families (18,618 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 18,591 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).